Baxter International (BAX) Gets a Buy Rating from Stifel Nicolaus

In a report issued on April 29, Rick Wise from Stifel Nicolaus maintained a Buy rating on Baxter International (BAXResearch Report), with a price target of $85.00. The company’s shares closed last Monday at $70.61, close to its 52-week low of $69.72.

According to TipRanks.com, Wise is a 5-star analyst with an average return of 9.5% and a 61.5% success rate. Wise covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Zimmer Biomet Holdings, and Edwards Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baxter International with a $91.90 average price target, which is a 28.8% upside from current levels. In a report issued on April 29, Raymond James also maintained a Buy rating on the stock with a $85.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Baxter International’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.71 billion and net profit of $71 million. In comparison, last year the company earned revenue of $2.95 billion and had a net profit of $298 million.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BAX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1931 and based in Illinois, Baxter International, Inc. provides a portfolio of healthcare products. The company focuses on transformative innovation to deliver smarter, more personalized care for patients and providers. It operates through six global businesses: Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery and Acute Therapies.

Read More on BAX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed